Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals

Area of Science:

• Oncology
• Drug Approval Processes
• Regulatory Science

Background:

• The U.S. Food and Drug Administration (FDA) established the accelerated approval program in 1992.
• This program allows drugs for rare or life-threatening diseases to reach the market faster than traditional pathways.
• A significant concern is that many drugs approved through this expedited route later fail to demonstrate definitive clinical benefits.

Purpose of the Study:

• To provide an overview of oncology drugs approved via the FDA's accelerated approval pathway.
• To identify and analyze oncology drugs that were subsequently withdrawn from the market.
• To examine the scope of cancer subtypes and therapeutic targets affected by these withdrawals.

Main Methods:

• Review of FDA accelerated approval records.
• Identification of oncology drugs approved since 1992.
• Analysis of drug withdrawal data for oncology indications.
• Categorization of drugs by cancer subtype and therapeutic target.

Main Results:

• Seventeen oncology drugs were approved through the accelerated pathway.
• These drugs covered 22 distinct cancer-related indications.
• A substantial number of these initially approved oncology drugs were later withdrawn.

Conclusions:

• The FDA accelerated approval pathway has been utilized for numerous oncology drugs.
• A notable proportion of these accelerated-approved oncology drugs did not maintain market presence due to lack of demonstrated clinical benefit.
• This highlights a critical need for robust post-market surveillance and confirmatory trials for drugs approved via expedited regulatory pathways, particularly in oncology.